Tirzepatide Peptide

Product Specifications

• CAS: 2023788-19-2
• Sequence: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(C20 diacid-γGlu-OEG-OEG linker)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
• Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular Mass: 4813.45 Da
• Purity: 99%+ (verified by HPLC)
• Appearance: White to off-white lyophilized powder

Storage

Compounded tirzepatide vials must be stored in a cool, dry place away from direct sunlight. Unreconstituted tirzepatide peptide should be kept at -20°C for long-term storage or 2-8°C for short-term storage. Once reconstituted with bacteriostatic water, tirzepatide should be refrigerated at 2-8°C and used within 28 days for optimal stability. Do not freeze reconstituted solutions. Always follow proper aseptic technique and storage guidelines to maintain product integrity for research applications.

Solubility

Tirzepatide compound is soluble in bacteriostatic water and sterile saline. Recommended reconstitution concentration is 1-5 mg/mL. Gently swirl the vial after adding solvent. Do not vortex or shake vigorously, as this may damage the peptide structure.

Intended Use

Tirzepatide is intended for research purposes only and is not approved for human use outside of FDA-approved branded formulations.

Tirzepatide Weight Loss Results and Body Composition Benefits

• In the landmark SURMOUNT-1 clinical trial, participants without diabetes achieved mean body weight reductions of 16.0% at 5 mg, 21.4% at 10 mg, and 22.5% at 15 mg over 72 weeks. Between 89% and 91% of participants receiving the 10 mg or 15 mg tirzepatide dosage achieved a clinically meaningful weight reduction of 5% or more.
• Tirzepatide treatment resulted in fat mass reduction approximately three times greater than lean mass reduction, improving overall body composition. In the SURMOUNT-4 continuation trial, participants who stayed on tirzepatide achieved a total mean weight loss of 26% from baseline.
• Research confirms that tirzepatide side effects during weight loss trials were predominantly gastrointestinal (nausea, decreased appetite) and generally mild to moderate. No significant increase in serious adverse events or all-cause mortality was observed across multiple trials.

How Does Tirzepatide Work for Glycemic Control and Appetite Suppression?

• Tirzepatide is a dual GIP/GLP-1 receptor agonist, the first compound to target both incretin pathways. This dual mechanism produces stronger effects on blood glucose regulation and weight reduction than either pathway alone. In a meta-analysis of 14 randomized controlled trials with 11,158 patients, tirzepatide reduced HbA1c by up to 9.84% and outperformed placebo, GLP-1 receptor agonists, and insulin across all measured parameters.
• Research shows tirzepatide improves insulin sensitivity and insulin secretory responses to a greater extent than semaglutide alone, with lower post-meal insulin and glucagon concentrations. This explains why switching from semaglutide to tirzepatide may provide additional metabolic benefits in certain research protocols.
• Decreased appetite was reported in 3.8% to 18.9% of participants across tirzepatide dosage groups, with all three doses producing greater appetite suppression than comparators. Studies indicate tirzepatide suppresses appetite and food intake through centrally mediated pathways, contributing to its weight loss effects.

Tirzepatide Benefits for Cardiovascular Health and Heart Failure

• The SUMMIT trial demonstrated that tirzepatide reduced the combined risk of cardiovascular death or worsening heart failure by 38% (hazard ratio 0.62) in patients with heart failure with preserved ejection fraction and obesity, over a median follow-up of 104 weeks.
• Heart failure events requiring hospitalization or IV medications were reduced by 59% (hazard ratio 0.41) in tirzepatide-treated patients compared to placebo. Participants also achieved 11.6% body weight reduction at 52 weeks, with significant improvements in 6-minute walk distance (+18.3 meters) and quality-of-life scores.

Tirzepatide Dosage for Research

Tirzepatide dosage used in preclinical and clinical research varies by study design, model, and administration route. Common dosing protocols in published literature include:

• Subcutaneous injection (clinical trials): 2.5 mg once weekly as a starting dose, escalated by 2.5 mg every 4 weeks to maintenance doses of 5 mg, 10 mg, or 15 mg weekly. The most common route across all major published tirzepatide studies.
• Subcutaneous injection (rodent models): 0.1–10 nmol/kg body weight, administered once weekly, used in metabolic, obesity, and glycaemic control studies.
• Intraperitoneal injection: Used in some preclinical rodent studies for consistent systemic delivery in pharmacokinetic and dose-response characterisation protocols.

Tirzepatide dosage frequency in research is once weekly, reflecting its approximately 5-day half-life. Statistically significant body composition and glycaemic changes typically require 8–12 weeks of sustained dosing. A peptide calculator can help scale published doses to a given reconstitution volume and injection unit.

Research Protocol Notes

This product is intended for research purposes only and should not be used for human consumption. It is strictly designated for laboratory and scientific use by qualified professionals. Common research applications include:

• In vitro cellular assays and cell culture studies
• Receptor binding profiling and signaling pathway analysis
• Analytical reference standards for High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS)
• Approved in vivo animal modeling to investigate physiological mechanisms and metabolic responses